Get in touch
contact@laverocktx.com
Poster presentation demonstrates the differentiated profile and broad applicability of the company’s gene silencing platform
London, UK, 15th May 2023 / Sciad Newswire / Laverock Therapeutics Ltd today announces that a key update on its proprietary and differentiated gene editing induced gene silencing (GEiGS) platform will be featured at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-20, 2023, in Los Angeles.
The data that will be presented at ASGCT demonstrates important stability, tunability and programmability attributes of the gene silencing approach in the context of iPSCs, primary T-cells and iPSC-derived myeloid cells. The presentation will provide fundamental insight into the power of the GEiGS platform for advanced cell therapy development, and its differentiation from classical gene editing and shRNA/siRNA approaches.
“This data opens up our ability to create a therapeutic pipeline of next-generation cell therapies in both regenerative medicine and immuno-oncology areas. We believe this technology can help solve many of the challenges remaining in the cell therapy field, ultimately improving efficacy, safety and accessibility,” said David Venables, CEO at Laverock Therapeutics.
“Laverock is continuing to develop its internal assets, while seeking partnerships and co-development options to expedite key activities. We look forward to providing further updates in the coming months.”
Details of the presentation are as follows:
- Title: Engineering Therapeutic Cells Through Rewiring of the miRNA Network
- Date/time of poster presentation session: Wednesday, May 17 at 12pm. Poster will be on display for the duration of the event.
- Lead author: Anna Klucnika
- Presenting author: Vlad C. Seitan
- Poster number: 759
- View the abstract
About Laverock Therapeutics
Laverock Therapeutics was established in 2021 to develop and commercialise the gene editing induced gene silencing (GEiGS) platform for human therapeutic applications. We believe this technology provides significant advantages over current approaches and enables the development of next-generation, programmable ex-vivo cell therapies.
Laverock has its headquarters in London, UK. For more information, please visit www.laverocktx.com and follow us on LinkedIn.
For further information, please contact:
Laverock Therapeutics
Sciad Communications
T: +44 (0)20 3405 7892
Stevenage, UK, 22 October 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October. Led by COO Tom Payne, Laverock’s team of scientists will be presenting three posters covering the Company’s technology platform and its application to CAR T cells and tumour microenvironment (TME) responsive macrophages for oncology. The data demonstrates the broad utility of the gene silencing technology for the development of differentiated therapeutic products. In contrast to other approaches, Laverock’s technology allows gene silencing that is programmable – linking silencing to cell identity or state; tunable – giving precise control of gene expression; stable – avoiding transient affects or epigenetic silencing; and specific – showing minimal loss or gain of function effects. It is also readily multiplexable, allowing targeting of multiple pathways in a single engineering step. Laverock’s product-focused posters demonstrate tunable, multiplex silencing of checkpoint pathways in primary T-cells, and use of phenotype-specific miRNA expression patterns to control macrophage function in response to TME cues. Tom Payne, COO of Laverock, said: “Over the last year we have generated a complete set of data in human cells demonstrating the unique features of our technology – namely its ability to silence genes in a programmable, tunable, stable and highly specific manner across a number of target genes and cell types. We believe this will enable the development of safer, targeted cell therapies by engineering human cells that exhibit gene silencing of the right genes, in the right cell, and at the right time.” Poster presentations: P: 0653. Klucnika, A et al Gene Editing induced Gene Silencing (GEiGS®) - A new technology to transform advanced therapies by programmable gene silencing. (Thursday 24.10.24 14:15 – 15:30). P: 0694. Houghton, B et al Programmable, multiplex CAR T cell engineered with Genome Editing induced Gene Silencing (GEiGs). (Thursday 24.10.24 18:00 – 19:30). P:0780. Menon, V et al Gene Editing induced Gene Silencing (GEiGS) technology to develop TME-responsive macrophages for solid tumour immunotherapy. (Thursday 24.10.24 18:00 – 19:30). ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries: Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner - Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting oncology and genetic diseases – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .
Stevenage, UK, 5 September 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces its conference attendance programme for the remainder of 2024. Forthcoming events include: ISCT Europe Regional Meeting , 4 – 6 September in Gothenburg - speaking Healthtech Innovation Day , 17 – 18 September in Paris - speaking, investor meetings Sachs Biotech in Europe Forum , 25 – 26 September in Basel - speaking, investor meetings and partnering Chardan Genetics Medicines Conference , 30 September – 1 October in New York - speaking, investor meetings and partnering ARM Meeting on the Mesa , 7 – 9 October in Phoenix, AZ – speaking, investor meetings and partnering TechBio UK 2024 , 16 October in London - panellist ESGCT Congress , 22 – 25 October in Rome - scientific presentations BioEurope , 4 – 6 November in Stockholm - investor meetings and partnering Cell 2024 , 6 – 8 November in London - speaking, session chair, panellist David Venables, CEO of Laverock, said: “We are excited to be showcasing recent advances in our technology at a number of key investor, scientific and partnering events. Over the course of 2024, Laverock has further validated its platform’s ability to silence genes in a programmable, tunable, stable and highly specific manner across multiple target genes and cell types. We have also broadened the platform’s potential by demonstrating the ability to silence more than one gene concomitantly. These developments further expand the range of potential applications for Laverock’s technology.” To arrange meetings with the Laverock leadership team at any of these events, please contact: contact@laverocktx.com ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries : Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner – Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .
Stevenage, UK, 26 March 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director. Ali has extensive experience in the biotechnology and pharma sector working with both private and public companies. She joins from Acacia Pharma Group plc, an early commercial-stage listed pharma company, where she was Group Financial Controller and Company Secretary and focused on equity fundraising, M&A activity and all aspects of financial operations. Prior to this, she spent 10 years as an auditor with PwC LLP in Cambridge, with a focus on early-stage biotech and pharma companies, together with advisory IPO work. She is a fellow of the Institute of Chartered Accountants in England and Wales and holds a degree in Archaeology and Anthropology from the University of Cambridge. In addition to Ali’s appointment, Laverock has significantly grown its team to 24 people, representing growth of 50% over the past year, and expanded its R&D facilities in the Stevenage Bioscience Catalyst as it continues to build its capabilities following its £13.5m expanded seed round announced in September last year, the second highest seed investment by a UK company in 2023. David Venables, CEO of Laverock, said: “Ali has an exceptional track record working with innovative biotechnology and pharma companies. I very much look forward to working closely with her and the rest of our fast-growing team as we continue to apply our uniquely powerful gene-silencing technology to the development of a new generation of programmable advanced therapies to tackle major diseases.” Ali Elsley, FD of Laverock, said: “Laverock’s technology has the potential to create a step-change in advanced therapies and I have been hugely impressed with the pace of progress since joining the company. The management team and Board are exceptionally strong, and I believe we have a very solid foundation from which to deliver on the promise.” ENDS For further information please contact: Laverock Therapeutics: E: contact@laverocktx.com Media Enquiries : Charles Consultants Sue Charles – Sue@charles-consultants.com +44 (0)7968 726585 Chris Gardner – Chris@CGComms.onmicrosoft.com +44 (0)7956 031077 About Laverock Therapeutics Laverock Therapeutics is a gene-silencing company with a uniquely powerful technology which harnesses the cell’s natural gene regulatory mechanisms to develop a new generation of programmable advanced therapies to tackle major diseases. Laverock’s truly innovative technology re-directs naturally-occurring micro RNAs (miRNAs) to conditionally silence genes in a way which is programmable, tunable, stable and specific. This opens a path to more effective, safer and accessible advanced therapies. Laverock is applying its technology through its own pipeline – targeting regenerative medicine and oncology – and through partnerships. Laverock has a highly experienced leadership team with proven track records in biotechnology, pharma and academia and an exceptionally strong Board. Laverock completed a £13.5m seed round in September 2023. Its high-calibre investors include Calculus Capital, Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund and Tekfen Ventures. For more information, please visit www.laverocktx.com and follow us on LinkedIn .
Speak to one of our team
To find out more about our technology and discuss partnering opportunities, please get in touch.
